Brief24Gilead is teaming up with Vir on solid tumor cancer drugs in a deal worth up to $1.9 billion
Quartz·
qz.comVir Biotechnology will receive $90 million upfront and could earn up to $1.74 billion in later milestone payments
qz.comChat about this story
Quick actions
